Lv4
472 积分 2024-12-27 加入
接受所有小饼干
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2天前
已完结
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
2个月前
已完结
Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma
2个月前
已完结
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
2个月前
已完结
The next generation of immunotherapies for lung cancers
5个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
5个月前
已完结
The present and future of bispecific antibodies for cancer therapy
5个月前
已完结
Zenocutuzumab: First Approval
5个月前
已完结
Iparomlimab and Tuvonralimab: First Approval
5个月前
已完结
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
6个月前
已完结
皖公网安备34019202002308
